anti-CD19 CAR NK cells

Phase 1Cell therapy

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

anti-CD19 CAR NK cells is one of 261 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

260

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Central Nervous System LymphomaActive, not recruiting

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

NephropathyActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Central Nervous System LymphomaPhase 1

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

LeukemiaPhase 1/Phase 2

Active, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Immune ThrombocytopeniaPhase 1

Active, not recruiting

NephropathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

anti-CD19 CAR NK cells

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1

2 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Nuvigil

NNuvo Research GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Immune Thrombocytopenia

NCT06337474

Q4 2026

Phase 1Recruiting

Rheumatoid Arthritis

NCT06613490

Phase 1/2Not yet recruiting

Cell Therapy

NCT06631040

Q1 2027

Phase 1Recruiting

Autoimmune Disease

NCT06318533

Q2 2027

Phase 1Recruiting

Nephropathy

NCT06469190

Clinical

Trials by Indication[1]

Autoimmune Disease2 trials

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Recruiting·—·Phase 1·NCT06464679·72 enrolled

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Recruiting·YYANRU WANG·Phase 1·NCT06318533·15 enrolled

Lymphoma2 trials

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Unknown status·—·Phase 1·NCT05673447·12 enrolled

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Unknown status·AAllife Medical Science and Technology Co., Ltd.·Phase 1·NCT03690310·9 enrolled

Systemic Lupus Erythematosus2 trials

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

Recruiting·—·Phase 1·NCT06010472·36 enrolled

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06421701·10 enrolled

Rheumatoid Arthritis1 trial

An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT06613490·24 enrolled

Immune Thrombocytopenia1 trial

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

Recruiting·—·Phase 1·NCT06337474·9 enrolled

4 more indications

Cell Therapy1 trial

Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL

Not yet recruiting·SShahid Beheshti University of Medical Sciences·Phase 1/2·NCT06631040·10 enrolled

Central Nervous System Lymphoma1 trial

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

Enrolling by invitation·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06827782·42 enrolled

Leukemia1 trial

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Unknown status·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT02892695·10 enrolled

Nephropathy1 trial

An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor NK Cell Injections (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

Recruiting·CChanghai Hospital·Phase 1·NCT06469190·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for anti-CD19 CAR NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-CD19 CAR NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-CD19 CAR NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PersonGen BioTherapeutics (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

anti-CD19 CAR NK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Autoimmune Disease2 trials

Lymphoma2 trials

Systemic Lupus Erythematosus2 trials

Rheumatoid Arthritis1 trial

Immune Thrombocytopenia1 trial

Cell Therapy1 trial

Central Nervous System Lymphoma1 trial

Leukemia1 trial

Nephropathy1 trial

References

Drug Info

Quick Facts

Related News